Skip to main content
Erschienen in: Psychiatric Quarterly 2/2008

01.06.2008 | Original Paper

Both Atomoxetine and Stimulants Improve Quality of Life in an ADHD Population Treated in a Community Clinic

verfasst von: Leo Bastiaens

Erschienen in: Psychiatric Quarterly | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

Objective

To evaluate change in quality of life in a community clinic ADHD population treated with atomoxetine or stimulants. No direct comparisons between atomoxetine and stimulants to improve quality of life in ADHD are available.

Methods

A prospective, nonrandomized comparison between ADHD patients treated with atomoxetine or stimulants in one clinic. Structured diagnostic assessment tools and a specific quality of life measure were used.

Results

84 patients (atomoxetine n = 39/stimulants n = 45), between the ages of 5 and 18, were treated for approximately 8 months. At end point, there were no significant differences in improvements of quality of life between the two groups. Age, participation in psychotherapy, and parental disability were not correlated with quality of life changes. Patients with lower baseline scores improved most.

Conclusions

Both atomoxetine and stimulants led to a modest increase in quality of life in this community clinic ADHD population.
Literatur
1.
Zurück zum Zitat Klassen AF, Miller A, Fine S: Health related quality of life in children and adolescents who have a diagnosis of ADHD. Pediatrics 114:e541–e547, 2004PubMedCrossRef Klassen AF, Miller A, Fine S: Health related quality of life in children and adolescents who have a diagnosis of ADHD. Pediatrics 114:e541–e547, 2004PubMedCrossRef
2.
Zurück zum Zitat Escobar R, Soutullo CA, Hervas A: Worse quality of life for children with newly diagnosed attention deficit hyperactivity disorder, compared with asthmatic and healthy children. Pediatrics 116:e364–e369, 2005PubMedCrossRef Escobar R, Soutullo CA, Hervas A: Worse quality of life for children with newly diagnosed attention deficit hyperactivity disorder, compared with asthmatic and healthy children. Pediatrics 116:e364–e369, 2005PubMedCrossRef
3.
Zurück zum Zitat Perwien AR, Faries DE, Kratochvil CJ, et al.: Improvement in health-related quality-of-life in children with ADHD: an analysis of placebo-controlled studies of atomoxetine. Journal of Developmental and Behavioral Pediatrics 25:264–271, 2004PubMedCrossRef Perwien AR, Faries DE, Kratochvil CJ, et al.: Improvement in health-related quality-of-life in children with ADHD: an analysis of placebo-controlled studies of atomoxetine. Journal of Developmental and Behavioral Pediatrics 25:264–271, 2004PubMedCrossRef
4.
Zurück zum Zitat Lopez FA, Chandler MC, Biederman J, et al.: Long-term Adderall XR treatment improves quality of life in ADHD children. Abstract presented at the 156th annual meeting of the American Psychiatric Association, 2003 Lopez FA, Chandler MC, Biederman J, et al.: Long-term Adderall XR treatment improves quality of life in ADHD children. Abstract presented at the 156th annual meeting of the American Psychiatric Association, 2003
5.
Zurück zum Zitat Bastiaens L, Dello Stritto C: Quality of life of children and adolescents during psychiatric treatment in a community mental health setting. Psychiatry 2:32–35, 2005 Bastiaens L, Dello Stritto C: Quality of life of children and adolescents during psychiatric treatment in a community mental health setting. Psychiatry 2:32–35, 2005
6.
Zurück zum Zitat Bastiaens L: Effectiveness and tolerability of atomoxetine in a real-world ADHD population. Psychiatry 4(12):44–48, 2007 Bastiaens L: Effectiveness and tolerability of atomoxetine in a real-world ADHD population. Psychiatry 4(12):44–48, 2007
7.
Zurück zum Zitat Sheehan DV, Lecrubier Y, Harnett Sheehan K, et al.: The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. European Psychiatry 12:232–241, 1997CrossRef Sheehan DV, Lecrubier Y, Harnett Sheehan K, et al.: The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. European Psychiatry 12:232–241, 1997CrossRef
8.
Zurück zum Zitat Gadow KD, Sprafkin J: Adolescent Symptom Inventory-4. Stony Brook, NY, Checkmate Plus LTD, 1997 Gadow KD, Sprafkin J: Adolescent Symptom Inventory-4. Stony Brook, NY, Checkmate Plus LTD, 1997
9.
Zurück zum Zitat Bastiaens L, Dello Stritto C: Validity and reliability of the Health and Life Functioning Scale. Abstract presented at the 51st annual meeting of the American Academy of Child and Adolescent Psychiatry, 2004 Bastiaens L, Dello Stritto C: Validity and reliability of the Health and Life Functioning Scale. Abstract presented at the 51st annual meeting of the American Academy of Child and Adolescent Psychiatry, 2004
10.
Zurück zum Zitat Geller D, Donnelly C, Lopez F: Atomoxetine treatment for pediatric patients with attention deficit hyperactivity disorder and comorbid anxiety. Journal of the American Academy of Child and Adolescent Psychiatry 46(9):1119–1127, 2007PubMedCrossRef Geller D, Donnelly C, Lopez F: Atomoxetine treatment for pediatric patients with attention deficit hyperactivity disorder and comorbid anxiety. Journal of the American Academy of Child and Adolescent Psychiatry 46(9):1119–1127, 2007PubMedCrossRef
11.
Zurück zum Zitat Prasad S, Harpin V, Poole L: A multicentre randomised open label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention deficit hyperactivity disorder. Current Medical Research and Opinion 23(2):379–394, 2007PubMedCrossRef Prasad S, Harpin V, Poole L: A multicentre randomised open label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention deficit hyperactivity disorder. Current Medical Research and Opinion 23(2):379–394, 2007PubMedCrossRef
12.
Zurück zum Zitat Bastiaens L: Pediatric psychopharmacology in a capitated managed care system: how do patients fare? Journal of Child and Adolescent Psychopharmacology 8(2):115–124, 1998PubMedCrossRef Bastiaens L: Pediatric psychopharmacology in a capitated managed care system: how do patients fare? Journal of Child and Adolescent Psychopharmacology 8(2):115–124, 1998PubMedCrossRef
Metadaten
Titel
Both Atomoxetine and Stimulants Improve Quality of Life in an ADHD Population Treated in a Community Clinic
verfasst von
Leo Bastiaens
Publikationsdatum
01.06.2008
Verlag
Springer US
Erschienen in
Psychiatric Quarterly / Ausgabe 2/2008
Print ISSN: 0033-2720
Elektronische ISSN: 1573-6709
DOI
https://doi.org/10.1007/s11126-008-9070-6

Weitere Artikel der Ausgabe 2/2008

Psychiatric Quarterly 2/2008 Zur Ausgabe

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.